Scholarlink

Purpose <p>To evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC).</p> Methods <p>This retrospective cohort included mBC patients receiving at least one cycle of SG (April 2021–May 2024) or T-DXd (February 2020–December 2024). Primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier curves and Log-Rank tests estimated and compared PFS and OS from treatment initiation. Subgroup analyses were performed by HER2 and hormone receptor status.</p> Results <p>48 patients received SG (24 RD vs. 24 SD) and 66 received T-DXd (29 RD vs. 37 SD). Median PFS for SG was 3&#xa0;months in both SD (95% CI, 2–10) and RD (95% CI, 2–8; p = 0.8). Median OS for SG was 10&#xa0;months (95% CI, 7–13) for SD and 11&#xa0;months (95% CI, 5–30; p = 0.4) for RD. For T-DXd, median PFS was 10.4&#xa0;months for SD (95% CI, 7.0–14.5) and 11.2&#xa0;months for RD (95% CI, 5.4–31.1; p = 0.8), while median OS was 18.3&#xa0;months (95% CI, 13.9–NA) for SD and 28.1&#xa0;months (95% CI, 18.2–NA; p = 0.9) for RD. Overall response rates were similar between patients receiving RD and SD SG or T-DXd.</p> Conclusions <p>This real-world data suggest RD of SG or T-DXd achieve outcomes comparable to SD, supporting prospective evaluation of lower-dose regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Nickolas Stabellini,
  • Jasskiran Kaur,
  • Cynthia Owusu,
  • Bahar Moftakhar,
  • Takae Mizukami,
  • Sonia D. de Oliveira,
  • Alberto J. Montero

摘要

Purpose

To evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC).

Methods

This retrospective cohort included mBC patients receiving at least one cycle of SG (April 2021–May 2024) or T-DXd (February 2020–December 2024). Primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan–Meier curves and Log-Rank tests estimated and compared PFS and OS from treatment initiation. Subgroup analyses were performed by HER2 and hormone receptor status.

Results

48 patients received SG (24 RD vs. 24 SD) and 66 received T-DXd (29 RD vs. 37 SD). Median PFS for SG was 3 months in both SD (95% CI, 2–10) and RD (95% CI, 2–8; p = 0.8). Median OS for SG was 10 months (95% CI, 7–13) for SD and 11 months (95% CI, 5–30; p = 0.4) for RD. For T-DXd, median PFS was 10.4 months for SD (95% CI, 7.0–14.5) and 11.2 months for RD (95% CI, 5.4–31.1; p = 0.8), while median OS was 18.3 months (95% CI, 13.9–NA) for SD and 28.1 months (95% CI, 18.2–NA; p = 0.9) for RD. Overall response rates were similar between patients receiving RD and SD SG or T-DXd.

Conclusions

This real-world data suggest RD of SG or T-DXd achieve outcomes comparable to SD, supporting prospective evaluation of lower-dose regimens.